Real-World check: does new IBD drug guselkumab deliver in the clinic?
NCT ID NCT07242248
First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times
Summary
This study tracks 220 adults with moderate-to-severe ulcerative colitis or Crohn's disease who are starting guselkumab, a biologic drug. Researchers will measure how many achieve remission (symptom control) and whether they can stop steroids. The goal is to see how well the drug works in real-world NHS clinics, not just in controlled trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLITIS, ULCERATIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
London North West University Healthcare NHS Trust
RECRUITINGHarrow, HA1 3UJ, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pregnancy and neurological disease coexist safely? a new registry seeks answers
- Could IBD medications during pregnancy shape a Child's development?
- AI reads scans to forecast Crohn's complications
- Can stem cell vesicles heal Crohn's fistulas?
- Can AI learn to grade endoscopy quality from video?
- Can a new drug calm the Gut's overactive immune response in Crohn's?